SONN Logo

Sonnet BioTherapeutics Holdings, Inc. (SONN) 

NASDAQ
Market Cap
$3.8M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
263 of 790
Rank in Industry
157 of 440

Largest Insider Buys in Sector

SONN Stock Price History Chart

SONN Stock Performance

About Sonnet BioTherapeutics Holdings, Inc.

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing …

Insider Activity of Sonnet BioTherapeutics Holdings, Inc.

Over the last 12 months, insiders at Sonnet BioTherapeutics Holdings, Inc. have bought $80,000 and sold $0 worth of Sonnet BioTherapeutics Holdings, Inc. stock.

On average, over the past 5 years, insiders at Sonnet BioTherapeutics Holdings, Inc. have bought $84,388 and sold $0 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Mohan Pankaj (Chairman, President and CEO) — $110,000. Rao Raghu (director) — $25,000.

The last purchase of 34,375 shares for transaction amount of $55,000 was made by Mohan Pankaj (Chairman, President and CEO) on 2023‑10‑27.

List of Insider Buy and Sell Transactions, Sonnet BioTherapeutics Holdings, Inc.

2023-10-27PurchaseChairman, President and CEO
34,375
2.7322%
$1.60$55,000+27.83%
2023-10-27Purchasedirector
15,625
1.2419%
$1.60$25,000+27.83%
2023-06-14PurchaseChief Technical Officer
10,000
0.0581%
$0.70$7,000-88.47%
2023-05-30Purchasedirector
23,255
0.1328%
$0.47$10,883-82.67%
2023-05-17Purchasedirector
25,000
0.1518%
$0.23$5,800-61.35%
2023-05-15PurchaseChairman, President and CEO
371,600
2.2431%
$0.22$82,867-59.81%
2023-03-15PurchaseChairman, President and CEO
60,000
0.3794%
$0.58$35,100-70.60%
2021-06-09PurchaseChairman, President and CEO
32,000
0.144%
$1.55$49,580-65.16%
2021-06-09PurchaseChief Medical Officer
15,000
0.0671%
$1.54$23,100-65.16%
2021-05-19PurchaseChief Medical Officer
10,000
0.0444%
$1.55$15,500-62.10%
2020-06-11Purchasedirector
2,409
0.0221%
$4.01$9,660-34.28%
2020-06-10PurchaseChairman, President and CEO
2,400
0.0216%
$4.09$9,816-36.76%
2020-03-23PurchaseCEO, Chairman
7,000
0.0699%
$0.58$4,078-78.31%
2020-03-23PurchasePresident
5,000
0.0433%
$0.51$2,528-78.31%
2020-01-31PurchaseCEO, Chairman
206
$0$0-82.68%
2019-12-10PurchaseCEO, Chairman
200
0.0004%
$0.62$124-77.56%
2019-11-19PurchaseCEO, Chairman
2,000
0.0039%
$0.70$1,410-80.36%
2019-11-17PurchaseCEO, Chairman
165
0.0003%
$0.64$106-76.27%
2019-08-23PurchaseCEO, Chairman
1,000
0.0008%
$0.57$572-65.73%
2019-08-19PurchaseCEO, Chairman
5,000
0.0036%
$0.61$3,050-70.41%

Insider Historical Profitability

<0.0001%
Mohan PankajChairman, President and CEO
59526
1.1442%
$0.7350<0.0001%
Rao Raghudirector
16813
0.3232%
$0.7310
SPITCAUFSKY LARRY
89689
1.724%
$0.7378
Kenney Richard TChief Medical Officer
50000
0.9611%
$0.7320
Pruitt Michael DCEO, Chairman
35462
0.6816%
$0.73740

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.